| 2.08 -0.01 (-0.48%) | 10-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.78  |
1-year : | 4.67 |
| Resists | First : | 3.23 |
Second : | 4 |
| Pivot price | 2.68 |
|||
| Supports | First : | 2 |
Second : | 1.67 |
| MAs | MA(5) : | 2.21 |
MA(20) : | 2.88 |
| MA(100) : | 4.23 |
MA(250) : | 3.9 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 4.6 |
| RSI | RSI(14): 18.8 |
|||
| 52-week | High : | 5.88 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATHE ] has closed above bottom band by 13.3%. Bollinger Bands are 63% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.36 - 2.38 | 2.38 - 2.39 |
| Low: | 1.98 - 1.99 | 1.99 - 2.01 |
| Close: | 2.06 - 2.08 | 2.08 - 2.1 |
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Fri, 23 Oct 2026
Alterity Therapeutics Ltd (NASDAQ: ATHE) Share Price, ATHE Stock News, ATHE Share Price & Updates - Kalkine
Fri, 23 Oct 2026
ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) - Stock Titan
Tue, 20 Oct 2026
ATHE Stock Price, Quote & News - Syfe
Mon, 19 Oct 2026
CEO David Stamler will speak at 2:30 p.m. ET on October 22 for Alterity (ATHE) at Craig-Hallum. - Stock Titan
Fri, 09 Oct 2026
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference - The Manila Times
Fri, 09 Oct 2026
Investor roundtables accompany Alterity Therapeutics (ATHE)'s planned Canaccord conference presentation. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 1.443e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 31 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.509e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 816.1 % |
| Return on Equity (ttm) | -34.1 % |
| Qtrly Rev. Growth | 3.61e+006 % |
| Gross Profit (p.s.) | 0.35 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -0.97 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 5.67 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 26110 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|